Indication
Small fiber neuropathy
Method
The analysis was performed with EIA. This method is not yet validated for clinical diagnostic use.
Answer
Results are reported as negative or positive with a value.
Interpretation
IgM-antibodies against TS-HDS are reported in a subgroup of patients with small fiber neuropathy (SFN) with unknown underlying cause. These antibodies activate complement and immune therapy may be effective, clinical trials are ongoing. TS-HDS IgM seems to be more frequent and specific for SFN than IgG-antibodies against fibroblast growth factor receptor 3 (FGFR3).
References
1. Farhad K. Current Diagnosis and Treatment of Painful Small Fiber Neuropathy. Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):103. PMID: 31773305.
2. Levine TD, et al. Muscle Nerve. 2020 Apr;61(4):512-515. doi: 10.1002/mus.26748. Epub 2019 Nov 6. PMID: 31650561.
3. Zeidman LA. Advances in the Management of Small Fiber Neuropathy. Neurol Clin. 2021 Feb;39(1):113-131. PMID: 33223078.
Indikation
Fintrådsneuropati
Metod
Analysen har utförts med EIA. Metoden är ännu inte validerad för klinisk diagnostik.
Svar
Svaret anges som negativt eller positivt med värde
Tolkning
IgM-antikroppar mot TS-HDS har rapporterats förekomma hos en undergrupp av patienter med fintrådsneuropati utan annan känd underliggande orsak. Antikropparna är komplementaktiverande och immunmodulerande behandling kan ha positiv effekt, kliniska studier pågår. TS-HDS IgM förefaller vara vanligare och mer specifika för fintrådsneuropati än IgG-antikroppar mot fibroblast growth factor receptor 3 (FGFR3).
Referenser
1. Farhad K. Current Diagnosis and Treatment of Painful Small Fiber Neuropathy. Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):103. PMID: 31773305.
2. Levine TD, et al. Muscle Nerve. 2020 Apr;61(4):512-515. doi: 10.1002/mus.26748. Epub 2019 Nov 6. PMID: 31650561.
3. Zeidman LA. Advances in the Management of Small Fiber Neuropathy. Neurol Clin. 2021 Feb;39(1):113-131. PMID: 33223078.